You are here: Industry Insights > Amgen

News List

Coherus BioSciences Announces Filing of Patent Infringement Suit Against Amgen Directed to Amgen’s Humira Biosimilar Formulation firstwordpharma
January 28, 2019
Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced it has filed suit against Amgen in the United States District Court (Delaware) alleging that Amgen's Humira® biosimilar, Amgevita™, infringes Coherus' U.S. patents
Coherus BioSciences Announces Filing of Patent Infringement Suit Against Amgen Directed to Amgen’s Humira Biosimilar Formulation firstwordpharma
January 28, 2019
Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced it has filed suit against Amgen in the United States District Court (Delaware) alleging that Amgen's Humira® biosimilar, Amgevita™, infringes Coherus' U.S. patents
CVS to cover migraine drugs from Teva, Lilly; excludes Amgen firstwordpharma
January 28, 2019
A spokesperson for CVS Health said that the company would exclusively cover new migraine drugs from Eli Lilly and Teva, as reported NASDAQ Friday.
Amgen, Allergan Announce Positive Top-Line Results from ABP 798 Study americanpharmaceuticalreview
January 25, 2019
Amgen and Allergan announced positive top-line results from a Phase 1/ Phase 3 study evaluating the pharmacokinetics, efficacy and safety of biosimilar candidate ABP 798....
Amgen’s Blincyto gets expanded indication for B-cell ALL in Europe pharmaceutical-technology
January 24, 2019
The European Commission (EC) has granted approval for the use of Amgen’s Blincyto as a monotherapy to treat adults with Philadelphia chromosome negative (Ph-) CD19 positive B-cell precursor acute lymphoblastic leukaemia (ALL)....
Amgen, UCB Receive Positive Vote from FDA in Favor of EVENITY Approval americanpharmaceuticalreview
January 21, 2019
Amgen and UCB announced strong support from the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval of EVENITY (romosozumab) for ....
Amgen and UCB receive positive vote from FDA Advisory Committee in favor of approval for EVENITY™ (romosozumab) worldpharmanews
January 21, 2019
Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) announced strong support from the U.S. Food and Drug Administration Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval of EVENITY™* (romosozumab)
FDA panel backs Amgen, UCB's postmenopausal osteoporosis drug Evenity firstwordpharma
January 17, 2019
An FDA advisory panel on Wednesday voted 18-1 that the benefits of Amgen and UCB's monthly injection Evenity (romosozumab) outweigh its risks for the treatment of osteoporosis in postmenopausal women at high risk for fracture.
Could Gilead, Amgen and AbbVie follow Bristol-Myers into megadeal territory? fiercepharma
January 08, 2019
Bristol-Myers Squibb’s Thursday announcement that it would nab Celgene for $74 billion brought “megamergers back to pharma,” as Credit Suisse analyst Vamil Divan put it in a note to clients. And the return has industry watchers wondering which company wil
Amgen teams with Entera to develop oral biologics fiercebiotech
December 27, 2018
Amgen has struck a deal with Entera Bio to develop oral formulations of up to three large molecules. The agreement sees Amgen pay a “modest” upfront fee to access Entera’s technology and commit to up to $270 million in milestones.......

Previous page 1 2 3 4 5 6 7 8 9 10 ... 22 23 Next page